NEW PHARMACEUTICALS FOR UNRESECTABLE OR METASTATIC MALIGNANT MELANOMA
This KCE has read for you was prepared by Lorena San Miguel and Nadia Benahmed
The Norwegian Knowledge Centre for the Health Services assessed in November 2015 the effectiveness and cost-effectiveness of seven new drugs for the treatment of unresectable or metastatic malignant melanoma in the adult population. Their review included evidence from 17 RCTs.
For overall survival (over a 2 year time horizon), nivolumab or pembrolizumab as monotherapies as well as the combinations of nivolumab+ipilimumab,
vemurafenib+cobimetinib and dabrafenib+trametinib have the highest probabilities of being superior to the other treatment strategies.
For safety, nivolumab and pembrolizumab have the lowest probability of serious adverse events but the quality of the evidence was rated as low.
- The cost-effectiveness evaluation including all interventions showed that at list prices in Norway, all new treatments had ICERs above € 100 000 per QALY.
published on 23-05-2016